Ophthalmology Times

Ophthalmology Times is a publication created by doctors for doctors, providing timely and precise news and insights related to clinical practices, socioeconomic issues, and political developments relevant to the eye care community.

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#356664

United States

#142609

Health/Medicine

#1168

Traffic sources

Monthly visitors

Articles

ARVO 2025: First in-human clinical trials results from magnetic cell therapy

2 days ago | ophthalmologytimes.com | Ellen Koo |Martin Harp |Hattie Hayes

Author(s):,Ellen Koo, MD, presented data from first in-human clinical trials, looking at the results from magnetic cell therapy and reports on the efficacy and safety in the patients. Editor's note: The below transcript has been lightly edited for clarity. Hi, my name is Dr Ellen Koo. I'm an associate professor of ophthalmology at Bascom Palmer Eye Institute. I am so happy to be here with you at ARVO 2025. We presented our work today at the poster sessions.
ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexylactane in dry eye

2 days ago | ophthalmologytimes.com | Jason Bacharach |Sheryl Stevenson |Hattie Hayes

Perfluorohexylactane may offer a fast-acting option for dry eye symptom relief, showing measurable benefits within minutes of application, explained Jason Bacharach, MD, who presented findings on the agent’s early efficacy at the 2025 American Society of Cataract and Refractive meeting, held April 25 to 28 in Los Angeles, California.
RWC 2025: BCVA and CST Improvement over 12 weeks with OCS-01 eye drops for DME

4 days ago | ophthalmologytimes.com | Sydney M Crago

David Almeida, MD, PhD, MBA, a vitreoretinal surgeon and clinician scientist, presented at the Retina World Congress about OCS-01, a new dexamethasone cyclodextrin formulation for diabetic macular edema (DME). The innovative eye drop technology offers promising efficacy and safety outcomes, addressing challenges in medication delivery to the back of the eye. By allowing longer contact times and better penetration, the formulation could potentially reduce treatment burden for patients.
RWC 2025: Katherine Talcott, MD, discusses the potential connection of auto-immune conditions to AMD

6 days ago | ophthalmologytimes.com | Sydney M Crago

Katherine Talcott, a retina specialist at Cole Eye Institute at the Cleveland Clinic, presented at the Retinal World Congress 2025 meeting. In her presentation and in her conversation with Ophthalmology Times, Talcott discussed the connection between autoimmune diseases and age-related macular degeneration (AMD), emphasizing the role of inflammation in AMD development. This large database study explored the link between autoimmune problems and AMD.
Perfuse Therapeutics announces positive results from phase 1/2a trial of PER-001, an intravitreal implant for glaucoma

6 days ago | ophthalmologytimes.com | Jordana Joy

Biopharmaceutical company Perfuse Therapeutics has announced positive 24-weeks results from its Phase 1/2a trial of PER-001, a first-in-class endothelin antagonist intravitreal implant for glaucoma.1 Data from the completed trial was presented at the Association for Research in Vision and Ophthalmology (ARVO) meeting earlier this week, according to a news release.
ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management

6 days ago | ophthalmologytimes.com | Deborah Ristvedt |Sheryl Stevenson |Hattie Hayes

Author(s):,Glaucoma management is shifting toward earlier, drop-sparing interventions using sustained drug delivery and advanced laser technologies that improve outcomes and quality of life for both patients and physicians. Deb Ristvedt, DO, moderated a session titled Medications, Lasers, and Lifestyle, highlighting the rapid evolution of glaucoma treatment paradigms at the 2025 American Society of Cataract and Refractive Surgery annual meeting, held April 25 to 28 in Los Angeles, California.
Innovent Biologics completes first patient dosing in its phase 2 clinical trial assessing efdamrofusp alfa in patients with DME

1 week ago | ophthalmologytimes.com | Jordana Joy

Biopharmaceutical company Innovent Biologics has completed the first patient dosing in its phase 2 clinical trial assessing efdamrofusp alfa for the treatment of diabetic macular edema (DME).1 The recombinant human vascular endothelial growth factor receptor (VEGFR)-antibody human complement receptor 1 (CR1) fusion protein was intravitreally administered in DME patients in the randomized, double-masked, multi-center, active-controlled trial (NCT06908876), which assessed the therapy’s efficacy...
Galimedix Therapeutics completes single ascending dose portion of phase 1 trial assessing GAL-101

1 week ago | ophthalmologytimes.com | Jordana Joy

Phase 2 clinical stage biotechnology company Galimedix Therapeutics has announced the completion of the single ascending dose (SAD) portion of its phase 1 study assessing the GAL-101, an oral therapy designed to treat Alzheimer disease, dry age-related macular degeneration (AMD), and glaucoma.1 The small molecule is specifically designed to target misfolded amyloid beta (Aβ) monomers, according to a news release.
Assessment of AI-enabled screening for ROP in low-resource settings

1 week ago | ophthalmologytimes.com | Lynda Charters

Anthony Ortiz, PhD, and colleagues recently reported that the access to screening for retinopathy of prematurity (ROP) can be expanded by using machine learning algorithms developed by using high-quality retinal images collected on a smartphone.1 Using this advanced technology would lift some of the burden off the few pediatric ophthalmologists that are available in that it could be used by lightly trained personnel who were not pediatric ophthalmologists to screen premature neonates for ROP...
NeuroOp Guru: Eye clues that signal neuroimaging in suspected neuro-Behcet disease

1 week ago | ophthalmologytimes.com | Andrew Lee |Andrew Carey

In this episode of NeuroOp Guru, Andrew G. Lee, MD, and Andrew Carey, MD, discuss the overlap between Behcet uveitis and neurologic involvement in Behcet disease, emphasizing the importance of coordinated care between uveitis and neuro-ophthalmology specialists. Behcet is a multisystem autoimmune disease that commonly affects the skin, vasculature, GI tract, and eyes. While uveitis is a hallmark finding, neuro-Behcet—though less common—is potentially life-threatening.